BRPI0913609A2 - composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas, uso do mesmo, método de depósitos de imagem de proteína agregada e kit para preparação de um composto detectavelmente marcado - Google Patents

composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas, uso do mesmo, método de depósitos de imagem de proteína agregada e kit para preparação de um composto detectavelmente marcado

Info

Publication number
BRPI0913609A2
BRPI0913609A2 BRPI0913609A BRPI0913609A BRPI0913609A2 BR PI0913609 A2 BRPI0913609 A2 BR PI0913609A2 BR PI0913609 A BRPI0913609 A BR PI0913609A BR PI0913609 A BRPI0913609 A BR PI0913609A BR PI0913609 A2 BRPI0913609 A2 BR PI0913609A2
Authority
BR
Brazil
Prior art keywords
compound
protein aggregation
protein
kit
preparing
Prior art date
Application number
BRPI0913609A
Other languages
English (en)
Inventor
Andrei Leonov
Armin Giese
Christian Griesinger
Hans Kretzschmar
Jens Wagner
Markus Geissen
Martin H Groschup
Mathias Habeck
Paul Tavan
Petra Frick
Sergey Ryazanov
Thomas Hirschberger
Uwe Bertsch
Original Assignee
Ludwig Maxmilians Uni Munchen
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40942347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913609(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ludwig Maxmilians Uni Munchen, Max Planck Gesellschaft filed Critical Ludwig Maxmilians Uni Munchen
Priority to BR122019022071A priority Critical patent/BR122019022071B8/pt
Publication of BRPI0913609A2 publication Critical patent/BRPI0913609A2/pt
Publication of BRPI0913609B1 publication Critical patent/BRPI0913609B1/pt
Publication of BRPI0913609B8 publication Critical patent/BRPI0913609B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
BRPI0913609A 2008-06-09 2009-06-09 composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit BRPI0913609B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019022071A BR122019022071B8 (pt) 2008-06-09 2009-06-09 composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08010458.1 2008-06-09
EP08010458 2008-06-09
PCT/EP2009/004144 WO2010000372A2 (en) 2008-06-09 2009-06-09 New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases

Publications (3)

Publication Number Publication Date
BRPI0913609A2 true BRPI0913609A2 (pt) 2015-11-24
BRPI0913609B1 BRPI0913609B1 (pt) 2020-02-18
BRPI0913609B8 BRPI0913609B8 (pt) 2021-05-25

Family

ID=40942347

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0913609A BRPI0913609B8 (pt) 2008-06-09 2009-06-09 composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit
BR122019022071A BR122019022071B8 (pt) 2008-06-09 2009-06-09 composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019022071A BR122019022071B8 (pt) 2008-06-09 2009-06-09 composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit

Country Status (21)

Country Link
US (3) US20110293520A1 (pt)
EP (3) EP2687513B1 (pt)
JP (3) JP5896739B2 (pt)
KR (1) KR101787112B1 (pt)
CN (1) CN102056903B (pt)
AU (1) AU2009266098B2 (pt)
BR (2) BRPI0913609B8 (pt)
CA (1) CA2726999C (pt)
CL (2) CL2010001369A1 (pt)
DK (2) DK2307381T3 (pt)
ES (2) ES2862923T3 (pt)
HU (2) HUE053352T2 (pt)
IL (1) IL208377A (pt)
MX (1) MX339144B (pt)
NZ (1) NZ588442A (pt)
PL (2) PL2684873T3 (pt)
PT (2) PT2684873T (pt)
RU (1) RU2531915C2 (pt)
TR (1) TR201904041T4 (pt)
WO (1) WO2010000372A2 (pt)
ZA (1) ZA201008820B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
JP5361316B2 (ja) * 2008-10-02 2013-12-04 株式会社タムラ製作所 表面処理剤、プリント回路基板およびその製造方法
PT2563920T (pt) 2010-04-29 2017-05-26 Ionis Pharmaceuticals Inc Modulação da expressão de transtirretina
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
GB201116017D0 (en) * 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
CN104693121B (zh) * 2014-11-14 2017-10-20 广州市爱菩新医药科技有限公司 一类具有抗老年痴呆活性的吡唑类化合物、制备方法与应用
JP6898931B2 (ja) * 2015-12-14 2021-07-07 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体
WO2017171053A1 (ja) 2016-03-31 2017-10-05 国立大学法人東北大学 シヌクレイノパチー治療薬
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
KR101956302B1 (ko) * 2016-11-30 2019-03-11 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3062749A1 (en) * 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
CN109726510B (zh) * 2019-01-23 2022-12-23 山东大学 一种蛋白质糖化位点鉴定方法
CN114728927A (zh) * 2019-11-19 2022-07-08 莫达戈有限公司 用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的新颖化合物
CN111138376A (zh) * 2019-12-24 2020-05-12 中山大学 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用
CN111848516B (zh) * 2020-08-04 2022-04-01 山东大学 溴酚-吡唑啉类化合物及其合成方法和应用
CN113045507B (zh) * 2021-03-04 2022-10-25 中山大学南方学院 一种3,4-二羟基苯甲酸甲酯衍生物及其制备方法与应用
CN113552102B (zh) * 2021-07-16 2022-05-17 上海交通大学 一种基于荧光相关光谱检测有机溶剂诱导蛋白聚集的药物筛选方法
EP4173485A1 (en) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control
CN114573570B (zh) * 2022-02-21 2023-05-30 中山大学 一类α-突触核蛋白靶向化合物及其制备方法和应用
AU2023227368A1 (en) * 2022-03-01 2024-07-18 Modag Gmbh Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
CN115650957B (zh) * 2022-09-16 2023-12-15 中山大学 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用
WO2024081385A1 (en) * 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
US11897850B1 (en) 2023-10-11 2024-02-13 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE581861A (pt) * 1958-08-20
CH426848A (de) * 1960-03-01 1966-12-31 Ciba Geigy Verfahren zur Herstellung von 1,3,4-Thiadiazolen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2104932A1 (en) 1970-09-08 1972-04-28 Ferlux O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc
US3907824A (en) * 1973-06-18 1975-09-23 American Cyanamid Co Preparation of 1-alkyl-3,5-diphenylpyrazoles and 1,2-dialkyl-3,5-diphenylpyrazolium salts
ZA744908B (en) * 1973-09-17 1975-08-27 American Cyanamid Co Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH04124178A (ja) * 1990-09-12 1992-04-24 Sds Biotech Kk 複素環式化合物および該化合物を含有する除草剤
DE4126543A1 (de) 1991-08-10 1993-02-11 Chem & Pharm Patent Hold Ltd 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
HUP0201586A2 (en) * 1999-06-10 2002-08-28 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
US20020002171A1 (en) 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
BRPI0113470B8 (pt) * 2000-08-24 2021-05-25 Univ Pittsburgh composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
CA2478068C (en) * 2002-03-08 2011-02-08 Merck & Co., Inc. Dihydropyrazole compounds useful for treating or preventing cancer
CA2484159C (en) * 2002-05-01 2011-02-22 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
SI2527315T1 (sl) * 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
TW200413009A (en) * 2002-10-04 2004-08-01 Univ Pennsylvania Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2004033432A1 (ja) * 2002-10-09 2004-04-22 Ssp Co., Ltd. 抗真菌活性を有する新規ピラゾール化合物
GB0225474D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1601657A1 (en) * 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
ES2770035T3 (es) * 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US20080255216A1 (en) * 2004-03-29 2008-10-16 Aster Susan D Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
AU2005245411B2 (en) * 2004-05-14 2009-04-23 Irm Llc Compounds and compositions as PPAR modulators
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
WO2006088711A1 (en) * 2005-02-14 2006-08-24 Wyeth AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS
TW200720254A (en) * 2005-04-07 2007-06-01 Nippon Kayaku Kk Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
WO2007002540A2 (en) 2005-06-24 2007-01-04 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
BRPI0709866B8 (pt) * 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
WO2008131148A1 (en) * 2007-04-19 2008-10-30 The Trustees Of The University Of Pennsylvania Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
JP2009203166A (ja) * 2008-02-26 2009-09-10 Nagasaki Univ ジフェニルオキサジアゾール誘導体含有診断用組成物
WO2009151529A1 (en) * 2008-05-14 2009-12-17 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
AU2009253046A1 (en) * 2008-05-30 2009-12-03 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion

Also Published As

Publication number Publication date
US10435373B2 (en) 2019-10-08
CL2014000270A1 (es) 2014-10-17
PT2307381T (pt) 2021-03-15
KR101787112B1 (ko) 2017-11-15
US20180346426A1 (en) 2018-12-06
US10071966B2 (en) 2018-09-11
WO2010000372A2 (en) 2010-01-07
PT2684873T (pt) 2019-04-26
IL208377A0 (en) 2010-12-30
BR122019022071B8 (pt) 2021-07-27
JP5896739B2 (ja) 2016-03-30
PL2684873T3 (pl) 2019-07-31
HUE053352T2 (hu) 2021-06-28
EP2307381A2 (en) 2011-04-13
US20110293520A1 (en) 2011-12-01
CN102056903B (zh) 2015-04-15
BR122019022071B1 (pt) 2020-12-29
WO2010000372A3 (en) 2010-05-27
IL208377A (en) 2017-11-30
JP6276744B2 (ja) 2018-02-07
US20160185730A1 (en) 2016-06-30
AU2009266098B2 (en) 2015-01-22
BRPI0913609B8 (pt) 2021-05-25
EP2687513A1 (en) 2014-01-22
JP2016102126A (ja) 2016-06-02
CA2726999A1 (en) 2010-01-07
CA2726999C (en) 2017-05-02
EP2687513B1 (en) 2020-12-02
JP2011522810A (ja) 2011-08-04
EP2684873A1 (en) 2014-01-15
PL2307381T3 (pl) 2021-07-05
HUE043090T2 (hu) 2019-08-28
CN102056903A (zh) 2011-05-11
EP2307381B1 (en) 2021-01-13
ZA201008820B (en) 2011-12-28
ES2862923T3 (es) 2021-10-08
NZ588442A (en) 2013-01-25
BRPI0913609B1 (pt) 2020-02-18
MX339144B (es) 2016-05-13
KR20110022666A (ko) 2011-03-07
CL2010001369A1 (es) 2011-06-17
JP2016121136A (ja) 2016-07-07
DK2307381T3 (da) 2021-03-15
JP6307060B2 (ja) 2018-04-04
RU2531915C2 (ru) 2014-10-27
RU2010154272A (ru) 2012-07-20
TR201904041T4 (tr) 2019-04-22
EP2684873B1 (en) 2019-01-16
MX2010012655A (es) 2010-12-21
AU2009266098A1 (en) 2010-01-07
DK2684873T3 (en) 2019-04-01
ES2714453T3 (es) 2019-05-28

Similar Documents

Publication Publication Date Title
BRPI0913609A2 (pt) composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas, uso do mesmo, método de depósitos de imagem de proteína agregada e kit para preparação de um composto detectavelmente marcado
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BRPI0821312A2 (pt) Controle não destrutivo, em particular para tubos em curso de fabricação ou no no estado acabado
SMT201500120B (it) Agenti di legame di notch e antagonisti di notch emetodi per il loro uso
BRPI0923500A2 (pt) uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0819127A2 (pt) Método para cimentar.
DK2139987T3 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
BRPI0813762A2 (pt) Dosador de produtos químicos para uso diário
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0818201A2 (pt) Composto de azolcarboxamida ou sal do mesmo
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
BRPI0817394A2 (pt) Método para processamento de pozzolans
BRPI0821746A2 (pt) Composto, uso do mesmo, composição, semente, método para controlar fungos fitopatogênicos, medicamento, e, processos para preparar um antimicótico e para preparar compostos
BRPI0808813A2 (pt) método para a preparação de compostos de borracha, e, uso de compostos
BRPI0810425A2 (pt) Método para determinação do risco de progressão de glaucoma
CL2008000237S1 (es) Mezclador para materiales viscosos.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0807377A2 (pt) Uso de rosiglitazona, 5-asa ou compostos, métodos para identificar agentes antiinflamatórios e/ou antimicrobianos, e para identificar agentes antiinflamatórios e antibacterianos potenciais, e, composição
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
BRPI0822069A2 (pt) Extraro de cardo leiteiro, método para preparação, e uso.
EP2019836A4 (en) METHODS, COMPOSITIONS AND KITS FOR DETECTING PROTEIN AGGREGATES
BRPI0814208A2 (pt) Composição para conferir agentes de benefício a substratos aniônicos, e métodos para seu uso.
BRPI0809664A2 (pt) punho auxiliar para ferramentas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF